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Abstract
 
Antigen-specific B cells express major histocompatibility complex class II and can present anti-
gen directly to T cells. Adoptive transfer experiments using transgenic B and T cells demon-
strated that antigen-specific B cells can also efficiently transfer antigen to another cell for pre-
sentation to T cells in vivo. To identify the antigen-presenting cell that receives antigens from
B cells, a strategy was developed to follow the traffic of B cell–derived proteins in vivo. B cells
were labeled with the fluorescent dye CFSE and loaded with antigen, before adoptive transfer
into recipient mice. Populations of splenocytes from the recipient mice were later assayed for
the presence of fluorescent proteins and for the ability to activate T cells. A small number of
CD8
 
 
 
 
 
CD4
 
 
 
CD11b
 
lo
 
 dendritic cells (DCs) contain proteins transferred from B cells and these
DCs effectively present antigens derived from the B cells to T cells. The results suggest that
CD8
 
 
 
 
 
 DCs sample the cells and membranes in their environment for presentation to T cells
circulating through the T cell zone. This function of CD8
 
 
 
 
 
 DCs may be relevant to the
priming of an immune response or the induction of T cell tolerance.
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Introduction
 
Intercellular communication is key to immune system
function and it has become clear that “conversations” be-
tween multiple cells are common and important (1–3).
Much focus has been placed on the roles of receptor–
ligand interactions in dialogs between pairs of cells, how-
ever these are not the only mechanisms of information
transfer between cells. Cellular communication includes
the exchange of cell components, such as the secretion
of exosomes (membranous vesicles; references 4–6), the
phagocytosis of dead cells (7, 8), and the direct uptake of
proteins from membranes (3, 9). The work described here
demonstrates that cell-associated antigen traffics between
antigen-containing cells in the blood and CD8
 
 
 
 
 
CD11b
 
lo
 
dendritic cells (DCs)
 
* 
 
in the spleen for presentation to naive
CD4
 
 
 
 T cells.
Antigen-specific B cells function as uniquely effective
antigen concentrating particles due to their ability to bind
antigen to their specific Ig receptors (10–12). Acutely acti-
vated B cells present this antigen complexed with MHC
class II to T cells to solicit help for proliferation and anti-
body production (13). We recently demonstrated that anti-
gen-specific B cell–T cell interactions in vivo occur both
directly between T and B cells, and indirectly, via an inter-
mediary APC. In this novel pathway of antigen-specific
lymphocyte regulation, antigen-specific B cells efficiently
transfer antigen to another APC in vivo for presentation to
T cells (2).
In this study, we set out to further characterize this pro-
cess and to identify the presenting APC. Our strategy was
to perform adoptive transfer of dye-labeled, HEL-loaded B
cells alone, with no T cells, then isolate the APC to which
the B cell transferred antigen from the recipient spleen.
Splenocytes from recipient mice which contained dye-
labeled proteins from the B cells were fractionated and
characterized by flow cytometry. The isolated populations
of cells were then tested for the ability to present antigen to
T cells in vitro. We show here that the presenting APC is a
CD8
 
 
 
 
 
 DCs which expresses high levels of MHC class II
and CD86. We propose that this subset of DCs constitu-
 
Address correspondence to Sarah E. Townsend, The Biomedical Re-
search Centre and Dept. of Medical Genetics, University of British Co-
lumbia, Vancouver, BC V6T 1Z3, Canada. Phone: 604-822-7810; Fax:
604-822-7815; E-mail: sarah@brc.ubc.ca
 
*
 
Abbreviation used in this paper:
 
 DC, dendritic cell. 
684
 
DCs Present Antigen from B Cells
 
tively samples the cells and membranes in its environment,
the T cell zone, and presents those cell-associated antigens
to T cells.
 
Materials and Methods
 
Mice.
 
Ig
 
HEL
 
 transgenic mice (13a) on the C57Bl/6 back-
ground, 3A9 TCR transgenic mice (13b) on the B10.BR back-
ground (
 
 
 
10
 
 
 
 backcrossed), B10.BR and B6 stock mice were
bred and maintained at the Biomedical Research Centre accord-
ing to University standards. Bcl-2 transgenic mice in the B6
background were purchased from The Jackson Laboratory. Bcl-
xL on the B6 background was a gift of Dr. Jeffrey Rathnell (Uni-
versity of Pennsylvania, Philadelphia, PA). The transgenic pheno-
types of all donor cells were verified by flow cytometry before
transfer into the recipient mice.
 
CFSE Labeling of T or B Cells.
 
T cells from spleen and lymph
nodes of transgenic TCR or B cells from spleens of Ig
 
HEL
 
 mice,
were labeled with 5-(and 6-) carboxyfluorescein diacetate succin-
imidyl ester (CFSE) modified as follows (14). The cells were
washed once with complete medium RPMI 1640, 10% FCS, 10
mM Hepes, resuspended at a concentration of 10
 
7
 
 cells per milli-
liter, incubated with 5 
 
 
 
M CFSE (Molecular Probes) for 7 min at
room temperature then washed with complete medium.
 
B Cell Purification and Antigen Loading.
 
CFSE-labeled trans-
genic B cells were purified using B220
 
 
 
 microbeads (Miltenyi
Biotec) as per the manufacturer’s instructions. Purified B cells, as
verified by FACS
 
®
 
 (92–98%) were loaded in vitro with 10 ng/ml
of HEL for 1 h on ice. The cells were washed in complete me-
dium and then in HBSS.
 
Adoptive Transfer.
 
CFSE-labeled transgenic T cells were
washed, counted, and resuspended in HBSS for injections. Cell
suspensions containing 1–3 
 
 
 
 10
 
6
 
 CD4
 
 
 
 cells were injected in-
travenously via the lateral tail vein. Several hours later or the next
day, cell suspensions containing 1–3 
 
 
 
 10
 
6
 
 HEL-specific trans-
genic B cells were intravenously injected. Recipient mice were
killed 14–16 h after the transfer, the spleens were collected, and
cell suspensions prepared for flow cytometry analysis.
 
In Vivo Protein Trafficking Experiments.
 
Transgenic B cells
were CFSE-labeled, then purified and HEL loaded as described
above. Then, the cells were washed, counted, and resuspended
in HBSS. The B220
 
 
 
 HEL-loaded transgenic B cells (3–6 
 
 
 
10
 
6
 
) were injected intravenously into B10.BR recipients. 12–14 h
after the injections the recipient mice were killed and the spleens
were collected for APC isolation. Each spleen was collected in
1 ml of RPMI 1640, 10 mM Hepes, and 0.01 mg/ml of Liberase
Blenzyme 3 (Roche Diagnostics), the spleens were minced with
razor blades and incubated for 1 h at 37
 
 
 
C. Fragments were dis-
sociated by passing five times through 21-g needle in order to
dissociate undigested material then washed twice with complete
medium.
 
In Vivo Protein Trafficking Experiments Using Bcl-2 and Bcl-xL
Mice.
 
Bead purified, CFSE labeled B cells from both transgenic
or nontransgenic mice were adoptively transferred into B10.BR
recipients by intravenous injection. 16 h after the transfer, the re-
cipients were killed and the spleens collected into 1 ml of RPMI
1640, 10 mM Hepes, and 0.01 mg/ml of Liberase and prepared as
above. The cell suspension then were stained and analyzed by
flow cytometry. To test the survival ability of the cells, both
transgenic or nontransgenic purified B cells were cultured in vitro
for 16–18 h in complete media. Then the cells were stained and
analyzed by flow cytometry.
 
In Vitro T Cell Activation.
 
Populations of APC isolated from
splenocytes of recipient mice were cultured in round-bottomed
96-well plates with 3A9 transgenic CD4
 
 
 
 T cells (3 
 
 
 
 10
 
5
 
 cells
per well) in complete medium with 10% FCS for 16 h at 37
 
 
 
C.
The cells were then stained and analyzed by flow cytometry.
 
Flow Cytometry.
 
Analytical flow cytometry was conducted on
a FACSCalibur™ and analyzed using CELLQuest™ (Becton
Dickinson) and FSCPress (Ray Hicks, University of Cambridge,
Cambridge, UK) software. Cell sorting was performed using
FACSVantage™ (Becton Dickinson). Antibodies specific for
CD69, CD11c, CD11b, and CD86 were purchased from BD
PharMingen. B220, CD4, CD8a, I-A
 
p
 
 were purchased from
Cederlane, and 7-AAD was purchased from Molecular Probes.
The hybridoma secreting the clonotypic anti-3A9 TCR anti-
body, 1G12, was a gift of D. Peterson, Washington University,
St. Louis, MO (15).
 
Biotinylation of Thymocytes.
 
3 
 
 
 
 10
 
7
 
 thymocytes were resus-
pended in HBSS and chilled on ice. Then the cells were incu-
bated for 30 min on ice with sulfo-NHS-biotin (Pierce Chemical
Co.) at a final concentration of 0.4 mg/ml. The cells were washed
and resuspended in HBSS plus 2% BSA. The effectiveness of the
biotinylation was measured by flow cytometry staining with
streptavidin-conjugated with allophycocyanin. The biotinylated
thymocytes were incubated with streptavidin (33 
 
 
 
g/ml; Sigma-
Aldrich) for 30 min on ice, then washed and incubated with
HEL-biotin for 1 h on ice and washed twice with HBSS.
 
Anti–Mouse IgM (
 
 
 
-IgM)–HEL Conjugation.
 
Purified HEL
was incubated with SMCC (succinimidyl 4-(
 
N
 
-maleimidomethyl)
cyclohexane-1-carboxylate; Pierce Chemical Co.) at 0.1 mg of
SMCC per mg of HEL, for 1 h at room temperature, under rota-
tion, and in the dark. Anti–mouse IgM (
 
 
 
-mIgM) was reduced in
20 mM DTT per ml of antibody at room temperature for 30 min.
HEL in SMCC and reduced 
 
 
 
-mIgM were passed over individ-
ual PD-10 columns previously equilibrated with 50 mM of MES
(2-[
 
N
 
-morpholino] ethanosulfunic acid, 2 mM EDTA), pH 6.0.
Derivitized HEL and reduced 
 
 
 
-mIgM were incubated for 1 h at
room temperature under rotation in the dark and the reaction
was stopped adding 34 ug of 
 
N
 
-ethylmaleimide. The conjugate
was isolated from free HEL by affinity chromatography on pro-
tein G and finally dialyzed into PBS, pH 7.8.
 
Results
 
We originally observed the presentation of antigen trans-
ferred from B cells in parental-into-F1 adoptive transfers
(H-2
 
bb
 
→
 
H-2
 
kb
 
; reference 2). This adoptive transfer system
permits the study of the trafficking of antigens associated
with cells present in the blood in which the donor cells
cannot directly present antigen to T cells. We subsequently
observed that the 3A9 HEL-specific TCR develops differ-
ently on the H-2
 
kb
 
 and the H-2
 
kk
 
 backgrounds, in that pos-
itive selection occurs more efficiently on the latter back-
ground (reference 16; data not shown). In light of these
results, we modified our transfer system to be fully alloge-
neic, H-2
 
bb
 
 donor B cells into H-2
 
kk
 
 recipient mice seeded
with H-2
 
kk
 
 3A9 T cells. Allogeneic CTL activity in the re-
cipient is not expected in the short time frame of the ex-
periments (16 h), but NK cell activity is expected. This low
level of acute allogeneic reactivity between donor cells and
recipients may amplify the trafficking of cell-associated an-
tigens in the blood (discussed further below). 
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Splenocytes from 3A9 TCR transgenic mice on the
B10.BR (H-2
 
kk
 
) background were adoptively transferred
intravenously into B10.BR recipients. The TCR trans-
genic splenocytes were labeled with the fluorescent dye,
CFSE, to aid in tracking the cells. MHC-mismatched (H-
2
 
bb
 
) transgenic Ig
 
HEL
 
 B cells were loaded in vitro with
HEL, at a dose of antigen that loads only the antigen-spe-
cific B cells and no other APC (unpublished data), or
sham-loaded. The MHC-mismatched, loaded transgenic B
cells were transferred intravenously into the same B10.BR
recipients previously seeded with HEL-specific T cells. 16 h
after transfer, recipient mice were killed and the spleno-
cytes prepared for flow cytometry. HEL-specific T cells
from recipient spleens were analyzed for the expression of
the early activation marker, CD69, as a measure of T cell
encounter with HEL peptide/I-A
 
k
 
 complexes.
Few CD4
 
 
 
 T cells from the recipients (CFSE
 
 
 
) ex-
pressed CD69, demonstrating that transfer of allogeneic B
cell did not induce measurable activation of the recipient’s
endogenous CD4
 
 
 
 T cells (Fig. 1 a and c). Similarly, HEL-
specific CD4
 
 
 
 T cells (CFSE
 
 
 
) from recipients which re-
ceived sham-loaded HEL-specific B cells were not acti-
vated (Fig. 1 b). In contrast, HEL-specific CD4
 
 
 
 T cells
(CFSE
 
 
 
) from recipient mice which received HEL-loaded
B cells were fully activated (Fig. 1 d). The activation of
these T cells was antigen-specific, as it required the pres-
ence of both the antigen, and the antigen-specific TCR
(Fig. 1 d). The experiment was also performed using puri-
fied CD4
 
 
 
 TCR transgenic cells, with similar results (data
not shown). The MHC class II–expressing APC that in-
duced this activation is resident in the recipient, as the
transferred B cells did not express the restricting MHC
haplotype. Accordingly, the antigen must have been trans-
ferred from the antigen-specific B cells to another APC in
the recipient for presentation to the T cells. The transfer of
antigen from B cells to endogenous APC in this fully allo-
geneic transfer system induces activation of naive, H-2
 
kk
 
 T
cells, similar to our original observation using the parental
into F1 transfer system (H-2
 
bb
 
 B cells into H-2
 
kk
 
; reference
2). The transfer of antigen for presentation to T cells does
not require the allogeneic difference, however, as T cell ac-
tivation was also efficiently induced after the transfer of
HEL-loaded H-2
 
bb
 
 B cells into tolerant recipients (H-
2
 
kk
 
→
 
H-2
 
bb
 
 bone marrow chimeras; Fig. 2).
We tested whether nontransgenic B cells have the ability
to transfer antigen as donor cells in vivo. Nontransgenic B
cells were loaded with HEL by incubating B6 splenocytes
with an anti-IgM antibody conjugated with HEL, to target
HEL to the BCR. Thymocytes were also incubated with
the antibody-HEL conjugate, to test the specificity of the
conjugate for B cells. As shown in Fig. 3 A, the anti–IgM-
HEL conjugate effectively loaded HEL on to the surface
of nontransgenic B cells, but not onto thymocytes.
HEL-loaded donor cells were adoptively transferred into
Figure 1. HEL-loaded, HEL-specific H-2bb B
cells mediate the activation of H-2kk-restricted
HEL-specific T cells in vivo. HEL-specific 3A9,
transgenic T cells from the B10.BR(H-2kk) back-
ground were labeled with CFSE and adoptively
transferred intravenously into intact B10.BR recip-
ients. Equal number of HEL-specific IgHEL trans-
genic B cells on the C57Bl/6 (H-2bb) background
were loaded with HEL in vitro or sham loaded,
then adoptively transferred into the recipients con-
taining transferred T cells. 16 h later, the recipient
mice were killed and the splenocytes analyzed by
flow cytometry. Files containing data for total lym-
phocytes as well as live-gated files containing data
only for CFSE  cells were collected for each sam-
ple. Data were gated for lymphocytes in FSC, SSC,
and B220  cells were eliminated from the analysis
by negative gating. T cell activation was measured
by the expression of the early activation marker
CD69 by nontransgenic CD4  T cells (a and c) or
by transgenic CFSE  CD4  (b and d). Data are
representative of three individuals from each of
more than eight experiments. 
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B10.BR recipients which had been previously seeded with
HEL-specific transgenic T cells. T cell activation was as-
sayed by flow cytometry 14 h after transfer. MHC-mis-
matched, HEL-loaded nontransgenic B cells mediated the
activation of HEL-specific T cells as effectively as HEL-
loaded transgenic B cells (Fig. 3 B). This result demon-
strates that the ability to transfer antigen in vivo is not pe-
culiar to transgenic B cells.
Intriguingly, the ability to transfer antigen is not a B
cell–specific phenomenon; any cell with membrane-associ-
ated antigen can transfer that antigen in vivo. HEL was
concentrated on the cell surface of thymocytes by first sur-
face biotinylating the cells, then incubating with streptavi-
din, and finally with HEL-biotin. These HEL-loaded thy-
mocytes were as effective as HEL-loaded Ig
 
HEL
 
 B cells in
transferring antigen in vivo (Fig. 4). We obtained similar
results using biotinylated L cells (data not shown). These
data demonstrate that B cell-specific molecules are not re-
quired for antigen transfer, and suggest that the antigen
transfer and presentation process is a general mechanism for
handling cell-associated antigen. B cells, however, may
represent a special case of this general mechanism, in that
they function here as antigen concentrating particles by
binding antigen via their antigen-specific Ig receptor.
We established the sensitivity of the T cell activation as-
say by transferring diminishing numbers of HEL-loaded
donor B cells. Transfer of 3 
 
 
 
 10
 
6
 
 donor cells induced high
T cell activation and transfer of 3 
 
 
 
 10
 
5
 
 cells induced sub-
stantial T cell activation (Fig. 5 A). In contrast, transfer of
3 
 
 
 
 10
 
4
 
 donor cells did not activate T cells. We showed
previously by Western analysis that 3 
 
 
 
 10
 
6
 
 HEL-trans-
genic B cells bind 
 
 
 
2 ng of HEL (2). By extrapolation, we
estimate that 
 
 
 
20 pg of antigen transferred by donor B
cells is required to induce T cell activation in this system.
Antigen transfer, processing, and presentation are re-
quired before T cell activation. The kinetics of T cell acti-
vation thus reflect the successful completion of these pro-
cesses. To determine the time frame in which antigen
transfer, processing and presentation occur in vivo
 
,
 
 adop-
Figure 2. Presentation of transferred antigen does not require an alloge-
neic response. HEL-specific IgHEL(H-2bb) transgenic splenocytes were
loaded with PBS or HEL ex vivo, and injected intravenously into B10.BR
(H-2kk) mice which had been previously seeded with CFSE-labeled 3A9
HEL-specific T cells (H-2kk) by adoptive transfer. 20 h after transfer, mice
were killed and the spleens prepared and analyzed by flow cytometry.
Data were gated to include lymphocytes and exclude dead cells, and for
CFSE  CD4  HEL-specific T cells. CD69 expression was used as a mea-
sure of T cell activation. Each point represent a single mouse.
Figure 3. Antigen concentrated by nontransgenic B cells is effectively
transferred for presentation to T cells in vivo. HEL was loaded onto non-
transgenic B6 B cells (H-2bb) using an anti-IgM antibody conjugated with
HEL to target HEL to the BCR. (A) HEL loading was measured by flow
cytometry using the HEL-binding antibody, HyHEL-9. The histograms
represent surface HEL on: IgHEL transgenic B cells after loading with HEL
(HEL), nontransgenic B cells after loading with anti–IgM-HEL conjugate
( IgM-HEL), nontransgenic thymocytes after loading with anti-IgM-HEL
conjugate (thymus), and IgHEL transgenic B cells after sham loading (Sham).
Data were gated for live lymphocytes and for B220  cells. (B) Loaded do-
nor cells were transferred into B10.BR recipients which had been previ-
ously seeded with CFSE-labeled 3A9 HEL-specific transgenic T cells. 14 h
after transfer, mice were killed and the spleens prepared for flow cytome-
try. Data were gated for live lymphocytes and either CFSE CD4  re-
sponder T cells (HEL-specific) or CFSE CD4  responder T cells (en-
dogenous), and activation was measured using CD69. Each point
represents a single mouse. Data are representative of two experiments. 
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B cells are preferentially excluded from the B cell follicles
in the presence of systemic antigen (17). B cells loaded with
antigen ex vivo then adoptively transferred by intravenous
injection are also excluded from the B cell follicles into the
T cell zone (Fig. 5 C). The excluded antigen-loaded B cells
are preferentially retained in the spleen (unpublished data),
which, together with the rapid kinetics demonstrated here,
strongly suggests that the APC which receives and presents
antigen is resident in the spleen.
Figure 4. HEL-loaded thymocytes transfer antigen for presentation to T
cells in vivo. HEL was loaded onto the surface of thymocytes by first sur-
face biotinylating the thymocytes, then incubating with streptavidin, then
finally incubating with HEL-biotin. Effective biotinylation and HEL-load-
ing were confirmed by flow cytometry. HEL-loaded B6 thymocytes or
HEL-loaded or sham-loaded B6 IgHEL B cells were injected intravenously
into B10.BR recipient mice previously seeded with CFSE-labeled HEL-
specific 3A9 transgenic T cells. 12–16 h later, mice were killed and spleens
prepared for flow cytometry. Data were gated on live lymphocytes and
CFSE CD4  responder T cells. CD69 expression was used as a measure of
T cell activation. The percentage of CFSE CD4  cells expressing CD69 in
mice receiving HEL-loaded IgHEL cells was considered maximal T cell acti-
vation and was  50% in both experiments. Data are presented from single
individuals in two separate experiments. Similar results were obtained in a
third experiment, except that the transfer of HEL-loaded thymocytes in-
duced 30% more activation than HEL-loaded IgHEL cells. Each point repre-
sents an individual mouse.
Figure 5. The percentage of HEL-specific T cells activation increases with the number of cells and the
time after adoptive transfer. (A) Varying numbers of HEL or sham-loaded, HEL-specific transgenic B
cells (H-2bb) were adoptively transferred into intact B10.BR mice (H-2kk), which had been previously
seeded with CFSE-labeled, HEL-specific transgenic T cells (H-2kk). 16 h later, the recipient mice were
killed and the splenocytes analyzed by flow cytometry. Squares represent sham-loaded and circles repre-
sent HEL-loaded transgenic B cells. (B) 106 HEL-specific transgenic B cells were adoptively transferred
into intact B10.BR mice which had been previously seeded with 106 CFSE-labeled, HEL-specific transgenic T cells. The recipient mice were killed at
different time point after the transfer and the spleens were prepared and analyzed by flow cytometry. Data were gated as in Fig. 1. (C) HEL-specific B
cells pulsed with HEL ex vivo and injected intravenously are excluded to the margins of the B cell follicles in the spleen. Splenocytes from IgHEL trans-
genic mice were pulsed with HEL or PBS alone, washed and transferred into intact syngenic recipients by intravenous injections. Mice were killed after
12 h and the spleens flash frozen. Cryosections were stained and analyzed by fluorescent confocal microscopy.
 
tive transfers were performed as described above and then
mice were killed at varying time points after B cell transfer.
T cell activation is detectable by 3 h after transfer and
 
 
 
30% of the T cells are activated by 6 h after transfer (Fig.
5 B). These results demonstrate rapid antigen transfer from
B cells injected into the blood to another APC for presen-
tation in vivo. T cell activation due to presentation of anti-
gen transferred from intravenously injected B cells was de-
tected in T cells in the spleen and not the lymph nodes (2). 
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We set out to isolate and characterize the APC by track-
ing proteins derived from the transferred B cells. In vitro
experiments using selectively depleted and enriched popu-
lations of APC suggested a role for CD11c
 
 
 
 DCs as the
dominant presenting APC (unpublished data). To track the
transfer of proteins from the B cells to other cells in the re-
cipient mice, the B cells were labeled with CFSE before
transfer. CFSE is a fluorescent dye that binds covalently to
proteins within the cells, and so can be used to track the
proteins of labeled cells (14). CFSE-labeled HEL-loaded B
cells were transferred into recipient mice without HEL-
specific T cells. The spleens of the recipient mice were
gently dissociated, stained, and analyzed by flow cytometry.
The transferred CFSE
 
 
 
 B cells were easily detectable
among the splenocytes (Fig. 6 A) as a small, very bright
population. Another distinct population of CFSE
 
med
 
 cells
was detected which was dimmer for CFSE than the trans-
ferred B cells, but easily distinguishable from CFSE
 
 
 
 cells.
Most of these CFSE
 
med
 
 cells express the DC marker,
CD11c (Fig. 6 A and B). The CD11c, CFSE
 
med
 
 population
represent, on average, 0.04% of total splenocytes and 1.4%
of CD11c
 
 
 
 cells. The diminished fluorescence in this small
population suggests that fragments of the B cells are associ-
ated with the cells. These fragments could be derived either
from whole cells that have been engulfed by DCs and are
being degraded, from membrane fragments, or from exo-
somes secreted by the B cells. The CD11c
 
 
 
, CFSE
 
med
 
 pop-
ulation does not express the B cell marker B220, suggesting
that B cell–derived fragments are within the DCs rather
than adhered to the DC cell surface (Fig. 6 B). The
CD11c
 
 
 
, CFSE
 
med
 
 cells express B220, do not express the
macrophage marker, F4/80, and are present in the CFSE-
labeled B cell population before transfer (data not shown)
and are likely to be poorly labeled transferred B cells.
Subpopulations of cells were sorted by flow cytometry
and tested for the ability to activate T cells in vitro. The in
vitro presenting activity of the total splenocytes from these
preparations varied between experiments, from undetect-
able to 15% of maximum T cell activation (Fig. 7), suggest-
ing that the presenting cell is rare and difficult to extract.
The majority of DCs, the CD11c
 
 
 
, CSFE
 
 
 
 population,
were very inefficient in activating T cells (Fig. 4). Similarly,
the CD11c
 
 
 
CFSE
 
med
 
 population was ineffective in activat-
ing T cells. In contrast, the small subpopulation of DCs that
contain proteins from the transferred B cells, which are
CD11c
 
 
 
CFSE
 
med
 
, were very efficient in activating T cells.
These data demonstrate that a CD11c
 
 
 
 cell receives anti-
gen from B cells in vivo, and that the cells effectively
present that antigen with MHC class II to T cells.
The CD11c
 
 
 
CFSE
 
med
 
 presenting population was char-
acterized further by analyzing the expression of mark-
ers for different known DC subsets (Fig. 8 A). The
CD11c
 
 
 
CFSE
 
med
 
 population expresses moderate CD11b,
no CD4 and high levels of CD8
 
 
 
 chain (Fig. 8 B). The
CD11c
 
 
 
 CFSE
 
med
 
 CD8
 
 
 
 
 
 population represents 5% (
 
 
 
1.9%) of the CD11c
 
 
 
CD8
 
 
 
 
 
 population, 1.4% (
 
 
 
 0.72%)
of the total CD11c
 
 
 
 population, and 0.04% (
 
 
 
 0.002%) of
the total splenocyte population (excluding red cells and
dead cells). The CD11c
 
 
 
 CFSE
 
med
 
 cells express MHC
class II and CD86 (Fig. 8 B) at levels which are high, but
which overlap with the levels expressed by the total
CD11c
 
 
 
 population.
To determine whether uptake of transferred material had
induced increased MHC class II and CD86 expression in
the CD11c
 
 
 
 CFSE
 
med
 
 population, this population was ana-
lyzed 2 and 6 h after donor cell transfer. As shown in Fig. 8
C, levels of these activation markers do not differ between
the early and later time points. These data suggest that the
levels of MHC class II and CD86 are constitutively high on
the DCs which receive transferred antigen.
CFSE
 
med
 
CD8
 
 
 
 
 
CD11b
 
lo
 
 DCs are present after syngenic
transfers of H-2
 
kk
 
 B cells into H-2
 
kk
 
 recipients, though at
frequencies approximately fourfold lower than after alloge-
neic transfer (Fig. 9). The observation that target DCs are
more numerous after an allogeneic transfer than after a syn-
Figure 6. A small subpopulation of CD11c1 cells acquires proteins
from fluorescent-labeled B cells. Purified HEL-specific transgenic B cells
on the C57Bl/6 (H-2bb) background were labeled with CFSE, loaded
with HEL, and adoptively transferred into unmanipulated B10.BR (H-2kk)
recipients. 12 h later the mice were killed and the spleens were gently
prepared, stained, and analyzed by flow cytometry. The very bright
CFSE , CD11c  population represents the transferred B cells (0.08%).
Data were gated using a wide FSC, SSC gate which included lympho-
cytes, large cells, and granular cells. Dead cells were eliminated from the
analysis by negative gating using 7-AAD. Data are representative of 20 in-
dependent experiments. (B) CFSE-labeled B cells are not adhered to the
surface of the DCs. The CFSEhi transferred B cells and the CD11c ,
CFSEmed populations identified in Fig. 2 were analyzed for the expression
of the B cell marker, B220, by flow cytometry. Data were gated as in
Fig. 2. The data are representative of three independent experiments. 
689
 
Valdez et al.
 
genic transfer suggests that the allogeneic response pro-
motes transfer, probably via cell death. The allogeneic
transfers are useful because direct T cell–DC interactions
are genetically isolated interactions from T cell–B cell in-
teractions. The syngenic transfers are useful because they
are more physiological, though direct T cell–DC interac-
tions cannot be distinguished from interactions from T
cell–B cell interactions. The transfer of antigen may occur
by different mechanisms in each case (discussed further be-
low), and it is interesting that the CFSE
 
med
 
CD8
 
 
 
 
 
CD11b
 
lo
 
DCs receive antigen in both cases.
We addressed the possibility that cell death contributes
to antigen transfer by testing whether transgenic overex-
pression of the antiapoptotic molecule bcl-2 by the donor
B cells changes the acquisition of transferred protein by
DCs (18, 19). Overexpression of bcl-2 by the donor B cells
decreases passive B cell death in vitro (Fig. 10 A and B) but
does not change the number of target DCs which receive
transferred protein in allogeneic transfers. Similar results
were obtaining using transgenic mice in which the B cells
overexpress bcl
 
XL
 
 (data not shown). These data suggest that
the differences we observe between the syngenic and allo-
geneic transfers are not due to death that can be rescued by
bcl-2, and that antigen transfer in both cases is unlikely to
depend on passive B cell death. In particular, these data
suggest that our ex vivo manipulations of the donor cells
(pulsing B cells with antigen) do not damage the cells and
induce passive cell death before or after transfer.
 
Discussion
 
CD8
 
 
 
 
 
CD11blo DCs loaded in vivo with cell-associated
antigen were directly identified and characterized for phe-
notype and function. Antigen-specific B cells efficiently
transfer antigen to another cell for presentation to T cells
(2). Nontransgenic B cells also transfer antigen, as do nonB
cells surface-loaded with antigen, which suggests that such
transfer is a general mechanism of antigen trafficking. Here
we show that this presenting cell is a CD8 -expressing
DC, which also expresses low CD11b and low CD4.
These DCs express higher levels of MHC class II and
CD86 than the total population of DCs, and these high
levels are constitutive rather than induced. DCs which re-
ceive transferred proteins effectively present antigen to T
cells ex vivo. Strikingly, bcl-2–mediated inhibition of
apoptosis had no effect on the transfer process. Together,
these results suggest that the CD8  CD11blo DCs constitu-
tively sample the cells and membranes in their environment
and present these cell-associated antigens to T cells.
Proteins derived from transferred HEL-loaded B cells
were visualized within a small subpopulation of DCs, and
this subpopulation efficiently presented B cell–derived
HEL to T cells ex vivo. The B cell proteins are likely to be
located within the DCs, as B220 was not detectable on the
surface of the DCs and the antigen accessed the MHC class
II pathway for presentation to T cells. The antigen is likely
transferred together with many other proteins derived from
the B cell, as presenting activity (demonstrating the pres-
ence of the antigen) corresponded with CFSE-labeling
(demonstrating the presence of B cell proteins). In other
recipient mice, proteins from B cells that were not loaded
with antigen (sham) were also detected within DCs. This
result demonstrates that B cell activation is not required for
the transfer of protein and suggests that the uptake of pro-
teins from other cells is a constitutive activity of these DCs.
Multiple subsets of DC have been identified in recent
years (20), including three subsets in the mouse spleen:
CD4 CD8  CD11bhi, CD4 CD8  CD11blo, and CD4 
CD8  CD11bhi. The CD4 CD8  CD11blo DC is lo-
cated in the T cell zones of the spleen and LNs and is
thought to be important in tolerance induction (21). It has
been known for some time that DCs can be either immu-
nogenic or tolerogenic (22–24), and immature DCs have
recently been shown to be tolerogenic in vivo in humans
(25). The relationship between the tolerogenic activity of
in vitro–generated immature DCs, and the activities of dif-
ferent DCs populations in vivo is not yet clear.
Different functions have been ascribed to the CD8  
and CD8   subsets, including the induction of IFN- –
producing Th1 cells via IL-12 by the former and the in-
duction of Th2 cells by the latter (26, 27). Liu et al. (29)
have proposed a corresponding nomenclature: DC1 and
DC2, with the caveat that there are substantial differences
Figure 7. Splenic DCs which receive transferred proteins in vivo
(CD11c , CFSEmed) directly activate HEL-specific T cells. Purified HEL-
specific transgenic B cells on the C57Bl/6 (H-2bb) background were la-
beled with CFSE, loaded with HEL ex vivo and adoptively transferred
into unmanipulated B10.BR (H-2kk) recipients. Populations of DCs were
tested for the ability to directly activate T cells in vitro. The CD11c 
CFSE , CD11c  CFSEmed, and CD11c  CFSEmed populations identified
in the Figure were sorted by flow cytometry and cultured overnight in
vitro with HEL-specific T cells. The purity of the sorted CD11c ,
CFSEmed population was 89%. Data were gated for live lymphocytes. In
the presence of exogenous HEL, 70.8% of HEL-specific T cells expressed
CD69, in the absence of antigen, 5.6% of HEL-specific T cells expressed
CD69. All points are data for three culture wells, except for one point,
without error bars in the total APC which represents the mean of two
wells. Error bars represent the SD. The functional data are representative
of six independent experiments.690 DCs Present Antigen from B Cells
between the mouse and the human DC systems (28, 29).
Our understanding of the function of these different subsets
is complicated by the plasticity of the phenotypes (29). For
example, both CD8  and DEC-205 expression can be up-
regulated upon activation in vitro by culture of DCs in the
presence of inflammatory mediators (30). It has been pro-
posed that CD8  CD11blo DCs are tolerogenic to T cells,
whereas CD4 CD8  CD11bhi DCs are immunogenic
Figure 8. Splenic DCs containing transferred proteins
express high levels of CD8 , I-A, and CD86. Purified
HEL-specific transgenic B cells on the C57Bl/6 (H-2bb)
background were labeled with CFSE, loaded with HEL ex
vivo, and adoptively transferred into unmanipulated
B10.BR (H-2kk) recipients. (A) Data were first collected
for total live cells, and then subsequent data were collected
using lived-gating on CD11c  to collect sufficient events
for analysis. (B) Lived-gated files were gated in the
CD11c , CFSE  and CD11c , CFSEmed populations iden-
tified in the Figure and were analyzed for the expression of
surface markers by flow cytometry. Data were gated as in
Fig. 6. The data are representative of three independent
experiments. (C) Stable surface phe-
notype of CD11c  CFSEmed early af-
ter donor cells injections. B6 spleno-
cytes (H-2bb) were labeled with the
dye CFSE and adoptively transferred
into B10.BR recipients (H-2kk) by
intravenous injection. The recipient
mice were killed 2–6 h after the in-
jections. Spleens were prepared and
analyzed by flow cytometry. The
CD11c  CFSE  and CD11c 
CFSEmed populations were identi-
fied, then analyzed for the expression
of surface markers. Data were gated
as in the Figure.691 Valdez et al.
(references 24 and 31; discussed further below), but much
of the work cited was performed in vitro.
Cross-presentation involves the acquisition of antigen
from genetically disparate cells for presentation to T cells
(24, 32, 33). MHC class I–mediated cross-presentation has
been described in a variety of murine models and has been
shown to be tolerogenic for CD8  T cells (32, 34). A re-
cent report identified the presenting cell in an MHC class I
cross-presentation system as a CD8   DC (35). In this
work, DCs from mice primed with antigen-loaded spleno-
cytes were sorted by flow cytometry and this bulk popula-
tion CD8  CD11c  DCs of cells was shown to present
antigen to MHC class I–restricted T cells. We show here
that the same, or very similar, subset of DCs is responsible
for MHC class II presentation of antigen received from B
cells. We directly identified and characterized the individ-
ual CD8  CD11c  cells that received transferred antigen
and presented that antigen with MHC class II to T cells,
and showed that they have an activated phenotype.
MHC class I and II pathways are generally distinct.
MHC class I presents primarily endogenous antigens and
MHC class II presents primarily exogenous antigens (36).
In CD8   DCs, however, the MHC class I pathway has
access to exogenous antigens. The observation that CD8  
DCs mediate both MHC class I cross-presentation and
MHC class II presentation of antigen transferred from B
cells suggests that these cells have a specialized function in
vivo. CD8   DCs may be specialized for sampling the cells
and membranes in their environment for presentation to T
cells circulating through the T cell zone (37). It was re-
cently shown that CD8   DCs do not present soluble an-
tigen to MHC class II–restricted T cells (38), which sup-
ports the notion that this subset of DCs is specialized to
present cell-associated antigens. Such antigen presentation
in the absence of additional inflammatory stimuli may be
tolerogenic to the T cells by inducing abortive proliferation
(2, 24). Indeed, this subset of DCs has recently been shown
to mediate tolerance of T cells in vivo when antigen was
delivered to DCs via the DEC-205 receptor (39). Further-
Figure 9. The number of DCs containing transferred proteins increases
linearly with the number of transferred donor cells. Varying numbers of
CFSE-labeled B6 (H-2bb) or B10.BR (H-2kk) splenocytes were adop-
tively transferred into B10.BR recipients by intravenous injection. 18 h
after the transfer, the mice were killed and the spleens were prepared and
analyzed by flow cytometry for the presence of CD11c CFSEmed cells.
Data were gated using a wide FCS, SSC gate that includes lymphocytes
and larger granular cells. Dead cells were eliminated by negative gating
using 7-AAD. Each point represents a single mouse. The data is represen-
tative of five independent experiments.
Figure 10. Overexpression of Bcl-2 by B cells decreases passive death in
vitro but does not affect DC acquisition of transferred proteins. (A) Puri-
fied B cells from C57BL/6 stock mice and from C57BL/6-TgN(22Wehi)
transgenic mice, which overexpress Bcl-2 were labeled with CFSE and
cultured in complete media for 16–18 h. The cells were then washed and
stained with 7-AAD and B220 and analyzed by flow cytometry. Data
were gated for B220  cells and 7-AAD was used as a measure of cell
death. Data represent the mean of triplicate cultures and error bars repre-
sent standard deviation. The data are representative of two independent
experiments. (B) Purified B cells were labeled with CFSE and injected in-
travenously into B10BR (H-2kk) recipients. 16 h later, mice were killed
and the splenocytes were prepared and analyzed by flow cytometry. Data
were gated to exclude dead cells and red blood cells. CD11c  and CFSE 
were gated and counted. Each point represent a single mouse. The data
represent three independent experiments.692 DCs Present Antigen from B Cells
more, delivery of a signal to CD40 switched the activity
from tolerance to priming.
The CFSEmedCD11c  express CD8  and low levels of
CD11b (CFSEmedCD8  CD11blo), which suggests that
these cells are interdigitating cells resident in the T cell
zone of the spleen (20, 21). The CFSEmedCD11c  DCs
also express elevated levels of CD86 and MHC class II,
phenotypes which are associated with activated or mature
DCs. The levels of activation markers in this subpopula-
tion, however, overlap significantly with those of the larger
DC population, so the extent of induced activation is un-
clear. A subset of cells may be constitutively activated, or
recent uptake of cellular material may activate the cells.
Intriguingly, this activated or mature phenotype of the
CFSEmedCD8  CD11blo cells is consistent with the phe-
notype observed in pulmonary DCs in mice treated with
antigen delivered nasally (40). DCs isolated from treated
mice express increased levels of MHC II and CD86, but
were tolerogenic upon transfer, and induced Tr1 cells by
an IL-10–dependent mechanism.
DCs have been shown to phagocytose both apoptotic
and necrotic cells and to present the antigens from those
cells in the context of MHC class I and II (7, 8, 41). The
phagocytosis of dead cells can induce activation of in vitro–
generated DCs, and this activation is associated with ne-
crotic rather than apoptotic cells. The activated phenotype
of CD8   DCs that contain B cell–derived proteins sup-
ports the possibility that phagocytosis of dead B cells is the
mechanism of antigen transfer in the experiments described
here. However, the vast majority of B cells transferred
were alive at the time of transfer, and enriching for live
cells did not improve presentation of antigen in vivo (data
not shown). The possibility remains that the transferred B
cells died in situ, and were then phagocytosed by CD8  
DCs. Inaba et al. demonstrated that fragments of dead, an-
tigen-loaded B cells can be phagocytosed by in vitro–gen-
erated DCs and that antigen from the B cells can be effi-
ciently transferred in vitro to DCs for presentation on
MHC class II molecules (8). They also showed that upon
adoptive transfer these loaded DCs migrate to the LNs in
vivo, and transfer the antigen to host DCs. Here we have
demonstrated that antigen transfer from B cells to DCs oc-
curs efficiently in vivo, with the functional consequence of
T cell activation.
Both self-tolerant and acutely activated B cells are ex-
cluded from B cell follicles into the T cell zones of lym-
phoid tissues (17, 42). In our system, antigen-pulsed B cells
are also excluded from the follicle into the margin with the
T cell zone. Accordingly, B cells which have bound anti-
gen preferentially colocalize with CD8   DCs, which are
also located in the T cell zone. In particular, excluded tol-
erant B cells, which have a short half-life of 1–2 d (17),
may be in the proper location to transfer antigen to
CD8   DCs upon their death. The self-antigens concen-
trated by the B cell could then be presented by the DCs via
MHC class I and class II to T cells. Although the transfer of
protein from B cells to CD8   DCs is not dependent on
the activation of B cells in our transfer model, it is possible
that activation, and thus the location of B cell death, may
be important at lower frequencies in vivo.
We are currently investigating the mechanism of antigen
transfer. In addition to the possibility that dead B cells are
phagocytosed by DCs, it is also possible that exosomes se-
creted by live B cells are internalized and processed by
DCs, or that membrane is extracted from B cells by DCs. B
cells have been shown to secrete in vitro small membra-
nous vesicles, or exosomes, which resemble MIIC com-
partments (4). Indeed, reticulocytes, platelets, B lympho-
blastoid cells, and DCs all secrete exosomes in vitro, which
raises the possibility that vesicle-mediated transfer of mole-
cules between cells may be a common form of information
transfer in vivo (4, 43, 44). Contact-dependent direct
membrane transfer between DCs was recently demon-
strated in vitro and represents a possible mechanism for the
transfer of antigen from B cells to DCs (37).
Our working model is that two concurrent mechanisms
of antigen transfer are operating in our system. The first
mechanism of antigen transfer is the DCs phagocytosis of
allogeneic donor cells killed by NK cells. It is likely that the
fully allogeneic system, the transfer of H-2bb donor cells
into H-2kk recipients, has allowed us to amplify what
would otherwise be a barely detectable process for handling
antigens derived from dead cells in the blood.
The second mechanism of antigen transfer is the transfer
of antigen from live B cells. Transfer of antigen from syn-
genic donor cells occurs and is not changed by the overex-
pression of bcl-2 (data not shown). In addition, we and
others have shown that live B cells produce particles that
transfer antigen (unpublished data). Accordingly, the trans-
fer of antigen from live donor cells to DCs is possible. Both
of these mechanisms, the phagocytosis of dead cells and
transfer of antigen from live cells, could contribute to nor-
mal antigen trafficking in vivo.
The MHC class II–mediated presentation by CD8  
cells that we describe here is unusual in that the antigens
are derived from antigen-specific B cells, which are them-
selves effective APC. The antigens concentrated by B cells
can be presented to T cells either directly by B–T interac-
tion, or indirectly by presentation by CD8   cells. Anti-
gen-specific B cells may concentrate circulating antigen too
dilute to be presented by other APC, then transfer this an-
tigen to CD8   DCs resident in the T cell zone of the
spleen for presentation to T cells. The important role for B
cells early in an immune response or in tolerance induction
may be to concentrate a unique subset of antigens. In this
way, the B cells would confer the unique properties of
their antigen-specific receptor onto another cell type. The
recipient cell, the CD8   DCs, may be specialized to re-
ceive this concentrated, cell-associated antigen for presen-
tation to T cells.
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